Drugs / Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00850603 | Oct 2002 → May 2003 | meningitis, meningococcal infection | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00850603 ↗ |
| Known as | Menomune - A/C/Y/W-135 | “Menomune® - A/C/Y/W-135” NCT00850603 ↗ |
| Modality | Vaccine | “Menomune vaccine” NCT00850603 ↗ |
| Route | Subcutaneous | “Subcutaneous” NCT00850603 ↗ |